This is hard to believe. I know Bristol Farms. They built

New Post Public Reply Private Reply Replies (1) Message Board
joey68 Mr.mando #61
This is hard to believe. I know Bristol Farms. They built the company around selling fresh products. And for some reason, a small store which sells organic chicken breast is now going to carry canned pancake batter? Will it go next to their chocolate macaroons?

So.. obviously investor excitement will ignore this post, but what ever happened to the promised ramped up production back in May 2015 due to the expectation of 'high demand' (quoted).

Just like I said back in july when the price was dropping from a penny: I wish all investors good luck, but I just don't see it happening.
Could I be wrong? Obviously.

If anything, this will run due to investor excitement/pump just like it did from April to June 2016.

Anyways... good luck to all invested. I like to post so I can keep track months down the road on how well my stock predictions end up.

See you all in 6 months.

Nate's Food Co. (NHMD) Stock Research Links

NHMD Board Company Profile Buy Rating Time & Sales News Filings Financials
View My Board Here:
http://investorshangout.com/Joeys-Investment-Board-91611/


Invite Only

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.

Disclaimer:
As used herein, the terms "You" and "Your" shall mean you, individually, the reader, and each other party on whose behalf you may use the contained information at any time.
All references to "My", "I", and “The writer of the above post” shall refer to the creator of the username Joey68.

Do NOT invest unless you are prepared to sustain a total loss of the money you have invested plus any commission or other transaction charges.

There is a very high degree of risk involved in trading and investing. Past results are not indicative of future returns. I assume no responsibility for your trading and investment results. You should NOT rely on the information in the above post to make any decision or take any action.

ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are OPINION and NOT fact and are for entertainment purposes only. Do your own research and make your own decisions based on your own conclusions.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are NOT advice, and are NOT designed to substitute the expertise and judgment of a professional. It is your responsibility to seek investment advice during all stages of your investments. It is your responsibility to evaluate the accuracy, completeness and usefulness of the information in the above post.
I am NOT a professional.
I do NOT work for you.
My posts are NOT investment advice. I am not paid to post.
There is no correlation between the number of posts I write per day and your assumed success of a company.
It is NOT my responsibility to inform you of my own personal investment decisions.
It is NOT my responsibility to inform you when it is time for you to buy, hold, and/or sell a position.
I have no control over, and am not responsible for the actions of others who copy, store, edit, change, prepare any derivative work of or alter in any way any of the content provided in my posts.
Errors and Omissions expected. The writer of the above post accepts no liability or responsibility for any errors or omissions contained in the above post or contained within this Disclaimer.
The writer of the above post shall NOT accept any liability for the accuracy or completeness of the information contained in the above post, for any reliance placed by any person on the information contained in the above post, or for any damage or loss, however caused, in connection with the use or reliance on any information contained in the above post.
The above post may contain links to websites owned and operated by third parties. These links are provided for informational purposes only and are NOT endorsed by the writer of the above post. The writer of the above post has no control over the contents of any linked website and bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.
YOU ACCESS ALL LINKS ENTIRELY AT YOUR OWN RISK.
The writer of the above post makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by, or the information contained on these websites.
The writer of the above post accepts no liability for any damage or loss, however caused, in connection with the use of or reliance on any information, material, products, or services contained on or accessed through any such linked websites.

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 34

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 39

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 31

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 45

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 41

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Cirba Solutions Welcomes Angie Stoskopf as VP of HR

Updated Category News Views 124

Cirba Solutions Welcomes New Executive Leadership Cirba Solutions, the leading battery recycling materials and management company, has announced the recent appointment of Angie Stoskopf as Vice President of People & Talent. This strategic decision underscores the company's commitment to enhancing its human resources capabilities, enabling them to support continued growth...

Continue Reading
Stay Warm This Winter With Mini-Split Heating Solutions

Updated Category News Views 65

Discover Efficient Heating with Mini-Split Systems As winter approaches and temperatures begin to drop, many homeowners are searching for effective and energy-efficient heating solutions. Mr. Mini Split is a leading provider in offering innovative mini-split heating and cooling systems that enhance comfort while maintaining energy efficiency. Why Choose Mini-Split...

Continue Reading
Leadership Changes at TowerCom Following Chris Colton's Passing

Updated Category News Views 1029

TowerCom Announces Significant Leadership Changes TowerCom, a seasoned developer of cell towers for over three decades, is thrilled to unveil pivotal leadership appointments aimed at furthering its growth and operational success. The company has elevated George Davis to the position of Chief Executive Officer, Matt Richard has been promoted to Chief Financial Officer,...

Continue Reading
Tencent Music's Strategic Growth Amidst Listener Decline

Updated Category News Views 201

Tencent Music's Robust performance amidst challenges Tencent Music Entertainment (NYSE: TME) recently showcased its impressive quarterly growth, gaining attention in the market as its shares surged. The latest financial results highlighted a revenue of $1.19 billion, reflecting a remarkable 20.6% increase year-over-year (Y/Y), a sign of strong demand and resilience in the...

Continue Reading
Bowen Acquisition Corp. Stock Hits Notable Low Amid Market Struggles

Updated Category News Views 192

Bowen Acquisition Corp. Experiences Significant Stock Movement In a financial landscape characterized by considerable fluctuations, Bowen Acquisition Corp. (BOWN) has seen its stock drop to a new 52-week low, hitting $10.08. This dip is noteworthy for a company with a market capitalization of around $100 million, particularly since BOWN is often recognized for its...

Continue Reading